TITLE

Placebo Controlled Double Blind Study with Pentoxifylline of Walking Performance in Patients with Intermittent Claudication

AUTHOR(S)
Di Perri, Tullio; Guerrini, Maurizio
PUB. DATE
January 1983
SOURCE
Angiology;Jan1983, Vol. 34 Issue 1, p40
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A double blind placebo-controlled randomised crossover study was performed with Pentoxifylline (Trental 400 tablets with 400 mg active ingredient) in 24 patients (19 males, 5 females, aged between 40 and 71 years) suffering from peripheral occlusive arteriopathy of stage II severity (Fontaine's classification). In 12 patients(group I) the treatment was started with placebo, and in another 12 subjects with Pentoxifylline (group II). The dosage was 3 tablets of either formulation t.d.s., the treatment periods were 8 weeks each with a two week washout between. The standardised walking test (120 steps/min under metronome control) was used for the assessment of the walking capacity. There was a significant 60% increase in pain-free walking distance in either Pentoxifylline treatment periods, whereas there were no clinically relevant changes in the placebo periods. When comparing the two starting periods only, there was an increase in the Pentoxifylline group from 223 to 359 m on average and in the placebo group from 208 to 215 m, patients in both groups being comparable at basal level as to the distribution of sex, age, location of occlusion, duration of disease as well as in respect to the walking capacity. No adverse reactions were recorded during the trial.
ACCESSION #
16438462

 

Related Articles

  • Pentoxifylline in the Treatment of Intermittent Claudication of the Lower Limbs. Reich, Theobald; Cutler, Bruce C.; Lee, Bok Y.; Porter, John M.; Reichle, Frederick A.; Scogin, John T.; Strandness, D. Eugene // Angiology;Jul1984, Vol. 35 Issue 7, p389 

    Pentoxifylline, a methyl xanthine analogue was evaluated for treatment of intermittent claudication in a double-blind placebo controlled parallel group study in seven centers in the United States. Tests were performed on 128 cases, including 42 who took pentoxifylline (600 mg by mouth daily,...

  • Effects of Flunarizine and Pentoxifylline on Walking Distance and Blood Rheology in Claudication. Perhoniemi, Vesa; Salmenkivi, Kari; Sundberg, Stig; Johnsson, Riitta; Gordin, Ariel // Angiology;Jun1984, Vol. 35 Issue 6, p366 

    Thirty-one patients, mean age 60 years (range 45–80 years), with a typical history and objective symptoms of intermittent claudication with a reported maximal walking distance less than 500 m. were included in a cross-over study. After a one month's run-in period on placebo, the patients...

  • Silence of the Limbs: Pharmacological Symptomatic Treatment of Intermittent Claudication. De Backer, Tine; Vander Stichele, Robert; De Buyzere, Marc; De Backer, Guy; Van Bortel, Lucas // Current Vascular Pharmacology;May2010, Vol. 8 Issue 3, p383 

    Several oral "vasoactive" drugs claim to increase walking capacity in patients with intermittent claudication (IC). Naftidrofuryl, cilostazol, buflomedil, and pentoxifylline are the most studied molecules. Although spanning several decades, several studies underlying these claims were not...

  • Is cilostazol more effective than pentoxifylline in the treatment of symptoms of intermittent claudication? Weismantel, David // Journal of Family Practice;Feb2001, Vol. 50 Issue 2, p181 

    This article presents a study which examined the effectiveness of cilostazol over pentoxifylline in the treatment of symptoms of intermittent claudication. The study population is composed of patients with stable moderate to severe symptoms of intermittent claudication and confirmed peripheral...

  • Pentoxifylline for Intermittent Claudication. Ernst, E. // Angiology;May1994, Vol. 45 Issue 5, p339 

    Pentoxifylline was first introduced in Germany twenty years ago. Today it is the best researched oral drug for intermittent claudication. A total of seventeen placebo-controlled trials could be retrieved from the world literature. The majority of these studies show that pentoxifylline will...

  • Acenocoumarol and Pentoxifylline in Intermittent Claudication. A Controlled Clinical Study. Dettori, Anton G.; Pini, Mario; Moratti, Alfio; Paolicelli, Mauro; Basevi, Paolo; Quintavalla, Roberto; Manotti, Cesare; Di Lecce, Carmelo // Angiology;Apr1989 Part 1, Vol. 40 Issue 4, p237 

    The efficacy and safety of pentoxifylline (400 mg tid orally) and acenocoumarol, administered singly or in combination, in the treatment of intermittent claudication associated with chronic occlusive arterial disease were evaluated in a multi-center, randomized, factorial, blind clinical trial...

  • The effect of pharmacological treatment on gait biomechanics in peripheral arterial disease patients. Huisinga, Jessie M.; Pipinos, Iraklis I.; Johanning, Jason M.; Stergiou, Nicholas // Journal of NeuroEngineering & Rehabilitation (JNER);2010, Vol. 7, p25 

    Background: Pharmacological treatment has been advocated as a first line therapy for Peripheral Arterial Disease (PAD) patients suffering from intermittent claudication. Previous studies document the ability of pharmacological treatment to increase walking distances. However, the effect of...

  • Placebo-Controlled Trial of Ketanserin in the Treatment of Intermittent Claudication. Cameron, H. A.; Waller, P. C.; Ramsay, L. E. // Angiology;Jul1987, Vol. 38 Issue 7, p549 

    The effect of ketanserin on the symptoms of 21 patients with stable intermittent claudication was examined in a double-blind, placebo-controlled, parallel-group study. Benefit was assessed by repeated treadmill exercise tests, recording claudication and total walking times. After three months'...

  • Evaluation of trans sodium crocetinate on safety and exercise performance in patients with peripheral artery disease and intermittent claudication. Mohler, Emile R; Gainer, John L; Whitten, Kim; Eraso, Luis H; Thanaporn, Porama Koy; Bauer, Timothy // Vascular Medicine;Oct2011, Vol. 16 Issue 5, p346 

    Trans sodium crocetinate (TSC) is a synthetic carotenoid that improves the diffusion of oxygen in animal models of ischemia/hypoxia. This study evaluated multiple doses of TSC in patients with peripheral artery disease (PAD) and hypothesized that a preliminary dose–response relationship...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics